F.D.A.’s Review of MDMA Cites Health Risks and Study Flaws
The New York Times
The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy.
The Food and Drug Administration on Friday raised concerns about the health effects of MDMA as a treatment for post-traumatic stress disorder, citing flaws in a company’s studies that could pose major obstacles to approval of a treatment anticipated to help people struggling with the condition.
The agency said that bias had seeped into the studies because participants and therapists were readily able to figure out who got MDMA versus a placebo. It also flagged “significant increases” in blood pressure and pulse rates that could “trigger cardiovascular events.”
The staff analysis was conducted for an independent advisory panel that will meet Tuesday to consider an application by Lykos Therapeutics for the use of MDMA-assisted therapy. The agency’s concerns highlight the unique and complex issues facing regulators as they weigh the therapeutic value of an illegal drug commonly known as Ecstasy that has long been associated with all-night raves and cuddle puddles.
Approval would mark a seismic change in the nation’s tortuous relationship with psychedelic compounds, most of which the Drug Enforcement Administration classifies as illegal substances that have “no currently accepted medical use and a high potential for abuse.”
Research like the current studies on MDMA therapy have corralled the support of various groups and lawmakers from both parties for treatment of PTSD, a condition affecting millions of Americans, especially military veterans who face an outsize risk of suicide. No new therapy has been approved for PTSD in more than 20 years.
“What’s happening is truly a paradigm shift for psychiatry,” said David Olson, director of the U.C. Davis Institute for Psychedelics and Neurotherapeutics. “MDMA is an important step for the field because we really lack effective treatments, period, and people need help now.”
For a century, exoplanet hunters have “discovered” planets around a nearby star, only to retract the claims. But the latest find is for real.
The unidentified patient had recently returned from Africa, where the virus has caused a deadly epidemic, health officials said.
The event produces some of the year’s fastest meteors, although the nearly full moon may make them challenging to spot.
Mr. Musk dug into his companies’ budgets, preferring to cut too much rather than too little and to deal with the fallout later. Under Donald Trump, he is set to apply those tactics to the U.S. government.
Behind the scenes at a Chicago zoo, chimpanzees who spent years entertaining humans are learning to befriend their own kind.
The agency’s top medical official was responding to rumors that Suni Williams had lost an unusual amount of weight during an extended stay in orbit.
Artificial intelligence has become a subject for people in the art and theater worlds who are worried about being replaced by it.
President-elect Trump says tariffs will help American businesses, but many in the wine industry foresee few benefits and a lot of pain for all involved.
Ball pythons were long assumed to be solitary, but scientists discovered the snakes in captivity prefer each others’ company when given the chance to live socially.
The Justice Department and four Democratic state attorneys general argued that United’s takeover would limit competition and harm consumers needing home or hospice care.
It took nearly 25 years for biologists to discover that a swimming and glowing organism in the ocean’s midnight zone was actually a sea slug.